Sheri McCoy

In early August 2017, Sheri McCoy was “terminated without cause” from her position as Avon CEO. She had been negotiating an exit since June. Sales had been depressed for several years.

In February 2012, after 30 years of employment with Johnson & Johnson, McCoy was passed over for a promotion to succeed William C. Weldon as chief executive officer. When Alex Gorsky, head of the industry trade association known as Pharmaceutical Research and Manufacturers of America (PhRMA) and CEO of Novartis was named to succeed Weldon, McCoy resigned from Johnson & Johnson, effective April 18, 2012.

In March 2012, French beauty products manufacturer, Coty attempted a takeover of Avon Products, presenting an unsolicited $10 billion buyout offer. The bid was rejected by Avon shareholders, who believed that the company was worth more, stating that the monetary offer was way below the market value that would be feasible under the leadership of a new Chief Executive Officer. On April 9, 2012, just two weeks after the takeover was rejected, it was announced that McCoy was chosen to lead Avon Products as their new CEO, effective April 23, 2012.

In 2008, McCoy was appointed to chair the Surgical Care Group. This leadership role established her as a member of the company's Executive Committee and one of the highest-ranking female executives in the global drug industry. On January 1, 2009, she was promoted to serve Johnson & Johnson as their Worldwide Chairman of the Pharmaceuticals Group, where she was responsible for new product development and distribution, along with acquisitions and partnerships. She also led the group during legal proceedings and loss of patent exclusivity. In 2010, she was promoted to Vice Chairman of the company.

McCoy joined Johnson & Johnson as a chemical engineer in 1982, where she focused on research and development of women's health products. She was eventually promoted to lead the company's research and development division, which was followed with a post as the global president of the division of the company that developed products that met the needs of infants, along with products that treated small injuries and wounds. In 2005, she was appointed to serve as the chairman of the Ethicon Endo-Surgery device division, where she was responsible for business in Latin America. She simultaneously served as a member of the Operating Committee of the Medical Device and Diagnostics Group.

Sherilyn S. McCoy (born 1959) is an American scientist and business executive. She is the former CEO of Avon Products and former vice chairman and member of the office of the chairman of Johnson & Johnson, where she was responsible for the pharmaceutical and consumer business divisions of the company. She was appointed as the vice chairman in January 2011, after which she was named by Fortune Magazine, as the 10th woman on their list of "50 Most Powerful Women in Business", a list on which she has been included since 2008. In February 2012, she resigned her employment with Johnson & Johnson after 30 years and was subsequently named as the CEO of Avon Products. In August 2012, she was recognized as the 39th most powerful woman in the world by Forbes Magazine.

Sherilyn S. "Sheri" McCoy was born in 1959, in Quincy, Massachusetts. She attended the University of Massachusetts, Dartmouth, earning her Bachelor of Science degree in textile chemistry. In 1982, she earned a master's degree in chemical engineering from Princeton University. She received her Master of Business Administration in 1988, from Rutgers University. She holds five patents registered in the United States and Europe.